Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-Interferon and Ribavirin in First Nations, Metis and Caucasian Ethnicity (PRAIRIE)
NCT00957866Phase 4Completed
- Sponsor
- University of Manitoba
- Start
- May 2009
- Primary completion
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated interferon alpha and ribavirin in hepatitis C (HCV), sponsored by University of Manitoba. Primary endpoint: Sustained Virologic Response. Started May 2009; status: completed.
02
Drugs
pegylated interferon alpharibavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00957866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00957866.